Breaking News

Covis Acquires Rights to Sanofi Drugs

April 5, 2013

Will promote five products in the U.S.

Covis Pharma Sarl has entered an agreement with sanofi-aventis U.S. and its affiliates to acquire full commercial rights to Nilandron, Plaquenil, Rilutek, Uroxatral, and Kayexalate in the U.S. The products are for prostate cancer, anti-malarial, ALS, Benign Prostatic Hyperplasia (BPH), and dangerously high levels of potassium in the blood, respectively. Together these products had sales of $114.6 million in the U.S. in 2012. Sanofi will retain the existing rights for these products outside the U.S.
 
Covis Pharma will promote these products through its U.S. distributor, Covis Pharmaceuticals, Inc. Sanofi will manufacture and supply the products for Covis Pharma.
 
"We are very pleased to announce the addition of these products to our existing portfolio," said Jack Davis, chief executive officer of Covis Pharma. "Covis will continue to supply consistent, top quality, branded pharmaceuticals, ensuring that patients receive the therapeutic care they need."
blog comments powered by Disqus
  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision

  • The Impact of Sample Handling  and Processing on the Outcome of Bioanalytical Testing

    The Impact of Sample Handling and Processing on the Outcome of Bioanalytical Testing

    Haiko Pillu, Head Technical Operations, Life Science Services, SGS Belgium NV||September 8, 2016
    Optimizing bioanalytical procedures to get reliable results in clinical studies

  • Quality Risk Management

    Quality Risk Management

    Cheryl Abernathy and Bryan Sasbon, Quality Assurance Operations Manager, Ropack Pharma Solutions; QA Director & Regulatory Affairs, Ropack Pharma Solutions||September 8, 2016
    Embracing the process as a means to a strong quality culture